S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Forecast, Price & News

$7.30
-0.29 (-3.82%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$7.21
$7.72
50-Day Range
$7.30
$13.23
52-Week Range
$7.21
$43.26
Volume
354,470 shs
Average Volume
309,319 shs
Market Capitalization
$366.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.31
30 days | 90 days | 365 days | Advanced Chart
Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Rhythm Pharmaceuticals logo

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Headlines

Cardiac Rhythm Management (CRM) Devices Market...
January 11, 2022 |  benzinga.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Strong Trading Volume
December 28, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
Employees
90
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.76 per share

Profitability

Net Income
$-134 million
Pretax Margin
-4,013.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
47,302,000
Market Cap
$366.96 million
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
1/22/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

802nd out of 1,418 stocks

Pharmaceutical Preparations Industry

384th out of 684 stocks

Analyst Opinion: 3.1Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

Is Rhythm Pharmaceuticals a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Rhythm Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RYTM, but not buy additional shares or sell existing shares.
View analyst ratings for Rhythm Pharmaceuticals
or view top-rated stocks.

How has Rhythm Pharmaceuticals' stock been impacted by COVID-19?

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RYTM stock has decreased by 51.3% and is now trading at $7.30.
View which stocks have been most impacted by COVID-19
.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Rhythm Pharmaceuticals
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.70) EPS for the quarter, beating the Zacks' consensus estimate of ($0.83) by $0.13. The company earned $1.03 million during the quarter. During the same period in the previous year, the company earned ($0.77) EPS.
View Rhythm Pharmaceuticals' earnings history
.

What price target have analysts set for RYTM?

6 brokerages have issued 12 month target prices for Rhythm Pharmaceuticals' shares. Their forecasts range from $14.00 to $67.00. On average, they anticipate Rhythm Pharmaceuticals' stock price to reach $33.83 in the next twelve months. This suggests a possible upside of 363.5% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:
  • David P. Meeker, Chairman, President & Chief Executive Officer
  • Hunter C. Smith, Chief Financial Officer & Treasurer
  • Alastair Garfield, Head of Research
  • Brieana Buckley, Vice President-Medical Affairs
  • Joseph Shulman, Senior Vice President-Technical Operations

What is 's approval rating as Rhythm Pharmaceuticals' CEO?

1 employees have rated Rhythm Pharmaceuticals CEO on Glassdoor.com. has an approval rating of 100% among Rhythm Pharmaceuticals' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $7.30.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals has a market capitalization of $366.96 million. The company earns $-134 million in net income (profit) each year or ($1.29) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

Rhythm Pharmaceuticals employs 90 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

Where are Rhythm Pharmaceuticals' headquarters?

Rhythm Pharmaceuticals is headquartered at 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at (857) 264-4280, via email at [email protected], or via fax at 857-264-4299.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.